CrossrefInfokarteSafety and efficacy of elexacaftor/tezacaftor/ivacaftor in children ≥2 years with cystic fibrosis: 96-week interim results from a phase 3 open-label extension study
Jennifer L. Goralski, Cori Daines, Jessica E. Pittman, Jonathan H. Rayment, Philip Robinson, Rebecca Thursfield, Florian Stehling, Felix Ratjen, Neil Ahluwalia, Peng Shi, Mengdi Lu, Tanya G. Weinstock, Marcus A. Mall, Ronald Gibson, Jennifer Goralski, Daniel Weiner, Carlos Milla, Jessica Pittman, Anne Stone, Alvin Singh, James Chmiel, Gregory Sawicki, Jordana Hoppe, Brooke Moore, Cori Daines, Felix Ratjen, Jonathan Rayment, Susanna McColley, Marcus Mall, Florian Stehling, Jane Davies, Rebecca Thursfield, Philip Robinson, Claire Wainwright, Barry Clements
Journal of Cystic Fibrosis · 2026-09 · 25 (5) · 778-785
DOI: 10.1016/j.jcf.2026.05.014 ↗